Dasatinib Sandoz 50 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 50 mg tabletti, kalvopäällysteinen

sandoz a/s - dasatinib - tabletti, kalvopäällysteinen - 50 mg - dasatinibi

Dasatinib Sandoz 20 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 20 mg tabletti, kalvopäällysteinen

sandoz a/s - dasatinib - tabletti, kalvopäällysteinen - 20 mg - dasatinibi

Dasatinib Sandoz 70 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 70 mg tabletti, kalvopäällysteinen

sandoz a/s - dasatinib - tabletti, kalvopäällysteinen - 70 mg - dasatinibi

DASATINIB SANDOZ 100 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 100 mg tabletti, kalvopäällysteinen

sandoz a/s sandoz a/s - dasatinibum - tabletti, kalvopäällysteinen - 100 mg - dasatinibi

DASATINIB SANDOZ 140 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 140 mg tabletti, kalvopäällysteinen

sandoz a/s sandoz a/s - dasatinibum - tabletti, kalvopäällysteinen - 140 mg - dasatinibi

Dasatinib Sandoz 50 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 50 mg tabletti, kalvopäällysteinen

dasatinib - tabletti, kalvopäällysteinen - 50 mg - dasatinibi

Dasatinib Sandoz 50 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib sandoz 50 mg tabletti, kalvopäällysteinen

dasatinib - tabletti, kalvopäällysteinen - 50 mg - dasatinibi

Dasatinib Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Euroopan unioni - suomi - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

DASATINIB RATIOPHARM 20 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

dasatinib ratiopharm 20 mg tabletti, kalvopäällysteinen

teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 20 mg - dasatinibi